washington reuters us congressional panel ask pharmaceutical entrepreneur martin shkreli testify jan 26 hear -PRON- company ’s decision raise price lifesave prescription drug accord republican committee staffer
shkreli become know " pharma bro " create fire storm last year -PRON- company ture pharmaceutical hike price drug call daraprim 5000 percent
last month shkreli force step turing ceo amid criminal civil security fraud charge allege -PRON- run ponzilike scheme -PRON- tenure hedge fund msmb capital management -PRON- ceo retrophin another drug company -PRON- previously head
security fraud charge unrelated drug pricing probe committee
hearing house representatives committee oversight government reform primarily focus ture ’s price spike daraprim price hike two valeant pharmaceutical ’s heart medication isuprel nitropress
democratic committee staffer tell reuter friday valeant ’s interim ceo howard schiller also expect appear hearing
valeant spokeswoman confirm schiller attend say -PRON- look forward testify company cooperate ongoing congressional probe
attorney shkreli decline comment
earlier month house oversight chairman jason chaffetz rank member elijah cumming jointly send document request valeant turing shkreli
-PRON- request lawmaker ask document show company ’s gross revenue profit sale drug question well communication ceo connection drug
since ture give ten thousand document -PRON- congressional investigator ahead hearing accord democratic committee staffer
spokeswoman turing immediate comment
committee expect review another batch document valeant near future
deadline submission jan 22
house oversight panel ’s interest drug pricing spark cumming year call republicanle panel probe prescription drug pricing
statement cumming say -PRON- glad bipartisan support investigation
-PRON- say americans " feed watch major drug company rake record profit -PRON- continue struggle afford -PRON- medicine "